非小细胞肺癌脑转移治疗的研究进展

肺癌是全球范围内发病率和死亡率最高的恶性肿瘤，非小细胞肺癌（non-small cell lung cancer，NSCLC）约占肺癌的80%，其中超过40%的晚期NSCLC患者在疾病病程中会发生脑转移，导致预后不良。传统的治疗方法如单纯放疗，化疗，外科手术对于改善肺癌脑转移的预后非常有限。近些年来随着立体定向放射治疗、靶向治疗的发展，尤其是化疗联合靶向，放疗联合靶向等交叉领域的联合治疗，NSCLC脑转移患者的生存质量得到提高，中位总生存期（median overall survival，mOS）得以延长。然而对于NSCLC脑转移的最佳治疗方案，仍然存在争议，本文将针对NSCLC脑转移领域的最新研究进展进行阐述，以期对肺癌脑转移患者选择合理治疗方案提供理论依据。 

Progress in the treatment of non-small cell lung cancer with brain metastases

Lung cancer is a malignant tumor, leading to the highest morbidity and mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer types. Out of all the patients with advanced NSCLC, more than 40% develop brain metastasis, and lung cancer associated with brain metastasis indicates poor prognosis. Traditional treatment options, such as radiotherapy, chemotherapy and surgery, have an extremely limited role in improvement of prognosis of such patients. In recent years, with the development of stereotactic radiotherapy and targeted therapy, particularly chemotherapy combined with targeted therapy, radiotherapy combined with targeted therapy and other types of therapies, NSCLC patients with brain metastases could benefit from these therapies with an improved quality of life and prolonged median overall survival. However, the ideal treatment regimen for NSCLC patients with brain metastases remains controversial. Recent advances in NSCLC with brain metastases will be described elaborately in this paper, to provide a theoretical basis for selecting a reasonable treatment plan for non-small lung cancer patients with brain metastasis.